Cost-Effectiveness of Administering Rituximab for Steroid-Dependent Nephrotic Syndrome and Frequently Relapsing Nephrotic Syndrome: A Preliminary Study in Japan.

Sci Rep · 2017 · PMC5384079 · PMID 28387313

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a clear trendno p-value reported

By contrast, the medical costs after adding rituximab showed a clear trend toward improvement, moving from 147,047 ± 32,054 points per 6 months to 89,676 ± 10,524 points per 6 months: as shown in Fig. 3 , this was 14,221 USD per 6 months at the start of the administration period, and 8,673 USD per 6 months after 18 months ( p < 0.01).

also in 19,460 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.